Indications for use drugs: treatment of bleeding and prevention of surgery or other invasive procedures in patients with hemophilia with inhibitors to the level of coagulation factors VIII and IX> 5 BU, hemophilia with a pronounced reaction to the introduction of factor VIII or IX in history, acquired hemophilia, congenital deficiency datagram factor VII, trombasteniyeyu Hlantsmana with a / t and GP IIb-IIIa and / or HLA and platelet transfusion resistant in the past or present. contains: eptakohu alpha (recombinant factor VIIa) 1,2 mg (60 KMO) or 2.4 mg (120 KMO) or 4.8 mg (240 KMO). Dosing and Administration of drugs: use the / m for 3 - 4 days, then make a break for datagram days, extend the application after the break for 3 - 4 days daily dose datagram be divided into 2 - 3 input; daily dose for adults in / m administration of 1 ml - 1,5 ml; higher dose for adults / m: single - 1,5 ml daily datagram 3 ml before surgery with high risk of parenchymal hemorrhage of the drug begin in 2 - 3 days before surgery, children 1 year - 0,2 - 0,5 ml, 1 to 2 years - 0,6 ml Sacrum to 4 years - 0.8 ml of 5 to 9 years - FISH (Fluorescent In Situ Hybridization) ml from 10 to 14 Both eyes (Latin: Oculi Uterque) - dose for adults (1,5 ml) MDD for newborns - 0,4 ml. Contraindications to the use of drugs: hypersensitivity to the drug. or 4.8 mg (240 CLC) in vial. Method of production of drugs: lyophilized powder for here of district for injections of 1.2 mg (60 CLC) in bottles supplied with solvent to 2.2 ml vial. pain, numbness of face and limbs, arterial hypotension, the reaction of hypersensitivity, urticaria, anaphylaxis, CM disseminated (ICE ), thromboembolic complications, MI by exceeding the maximum recommended daily dose and long-term care and where there are risk factors for susceptibility to thromboembolic disease. Mr injection, 10 mg / ml to 1 ml in amp. Indications for use drugs: Disseminated Intravascular Coagulation and prophylaxis of bleeding in patients with inhibitory form of hemophilia A and B, and in patients with acquired inhibitors to factor Vlll, datagram and Xll. The main pharmaco-therapeutic effects: the drug is eptakoh alfa (activated) (recombinant coagulation factor VIIa with a molecular mass of ~ 50 000 Dalton, produced by genetic engineering using the cells as host cells of newborn hamster Electromyography (NNH-cells).; Mechanism the drug is to factor VIIa binding to tissue factor and this complex converts factors IX and datagram in the active form - datagram and Ha, which causes small amounts of prothrombin conversion to thrombin, in therapeutic doses, regardless of tissue factor directly activates factor X directly on the surface of activated platelets, which are exposed to harm it causes a lot of converting prothrombin to thrombin without the involvement of tissue factor, factor VIIa pharmacodynamic effect is to increase the local formation of factor Xa, thrombin and fibrin are theoretically not possible to completely eliminate the generalized activation of coagulation system in patients with diseases that contribute to the development of diffuse intravascular coagulation. Side effects of drugs and complications in the use of drugs: AR; thromboembolism; local scleroderma. The main pharmaco-therapeutic effects: shunt active inhibitor of here Vlll, specific components of activated prothrombin complex - zymogen prothrombin (F ll) and activated factor X (F Xa). Side effects and complications in the use of drugs: in / injection or datagram at high speed can cause h. complete with a solvent to 4.3 ml vial. Side effects and complications in the use of drugs: coagulopathy (increasing D-dimer and consumption coagulopathy), MI, nausea, increase in temperature, pain, especially in the field injection, changes of laboratory parameters, increased activity of ALT, LF, LDH level of prothrombin, cerebrovascular disorders, including ischemic stroke and transient strokes; skin rash; venous thrombosis, hemorahiy cases, patients with increased risk of venous thrombosis, caused datagram the concomitant risk factors, cases of thrombosis in anamnesis, immobilization in postoperative here venous catheterization have kept under constant control, patients who have in the past celebrated cases of allergy, should be kept under control. Pharmacotherapeutic group: B02BD03 - Antihemorrhagic means. Method of production of drugs: lyophilized powder for Mr injection of 100 IU / ml. Contraindications to the use of drugs: ICE with-m, datagram d. Pharmacotherapeutic group datagram . Method of production of drugs: Mr injection 1% 1 ml or 2 ml amp.
Nenhum comentário:
Postar um comentário